Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

Hemasphere. 2024 Jul 24;8(7):e136. doi: 10.1002/hem3.136. eCollection 2024 Jul.
No abstract available